Contineum Therapeutics, Inc. (CTNM) — Stock Valuation & Research

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly…

CTNM key statistics

Price$9.69
Market cap$319.37M
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range6.725-17.79
Beta0.75

Explore CTNM's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.